Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$576.3MCash on Hand
CF+ Cash Runway
Follow KNSA by emailGet an email when KNSA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about KNSA, unsubscribe in one click. Privacy
📣 What KNSA Says Is Next
by the end of 2026 · “Kiniksa expects to initiate a Phase 1 first-in-human clinical trial of KPL-1161 with a target profile of quarterly subcutaneous (SC) dosing by the end of 2026. Financial Results”
Company press release, Oct 27, 2026 · SEC filing
second half of 2027 · KPL-387: “Kiniksa is enrolling and dosing patients in the Phase 3 pivotal trial of KPL-387 in recurrent pericarditis, PASTORALE, and expects data in the second half of 2027.”
Company press release, Oct 27, 2026 · SEC filing
this year · “We remain on track to initiate a Phase 1 trial of KPL-1161 by the end of this year.” Portfolio Execution ARCALYST (IL-1α and IL-1β cytokine trap)”
Company press release, Oct 27, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Oct 27, 2026 ·
Earnings Kiniksa reported Q3 2026 ARCALYST net product revenue of $286.0 million, up from $180.9 million in Q3 2025, and raised 2026 ARCALYST net product revenue guidance to $1.045 to $1.050 billion. Net income was $47.3 million and cash totaled $568.8 million. Form 8-K · SEC filing · Press release
Oct 27, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 22, 2026 ·
Leadership Ross Moat was appointed President and Chief Operating Officer effective October 17, 2026, reporting to Chairman and CEO Sanj K. Patel. Effective January 1, 2027, his base salary rises to $700,000 from $650,000 and his target bonus to 60% from 55%. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2027 · Phase 2 · Recruiting · Transition to KPL-387 Monotherapy Dosing & Administration Study Registry primary completion date, not a results date
Dec 2027 · Phase 2/3 · Recruiting · Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387 Registry primary completion date, not a results date
Mar 2029 · N/A · Active Trial · REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not KNSA's own candidates): Prednisone.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
KNSA holds $576.3M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure:0 · Low
No operating cash burn in latest filings
Recent financing filings on SEC EDGAR:
Jun 28, 2024 · Shelf registration, up to $400M · S-3
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KNSA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.